The most advanced P. falciparum circumsporozoite protein-based malaria vaccine, RTS,
S/AS01 (RTS, S), confers partial protection but with antibody titers that wane relatively …

Background Plasmodium falciparum circumsporozoite protein (CSP) is a leading malaria
vaccine candidate antigen, known to elicit protective antibody responses in humans (RTS, S …

The N-terminal domain of the circumsporozoite protein (CSP) has been largely neglected in
the search for a malaria vaccine in spite of being a target of inhibitory antibodies and …

Plasmodium falciparum vaccine RTS, S/AS01 is based on the major NPNA repeat and the C-
terminal region of the circumsporozoite protein (CSP). RTS, S-induced NPNA-specific …

Studies in animals and human volunteers demonstrate that antibodies against the repeat-
region of the Plasmodium circumsporozoite protein (CSP) abrogate sporozoite infection …

The circumsporozoite protein (CSP) of Plasmodium falciparum is a major surface protein,
which forms a dense coat on the sporozoite's surface. Preclinical research on CSP and …

For some diseases, successful vaccines have been developed using a nonpathogenic
counterpart of the causative microorganism of choice. The nonpathogenicity of the rodent …

The repeat region of the Plasmodium falciparum circumsporozoite protein (CSP) is a major
vaccine antigen because it can be targeted by parasite neutralizing antibodies; however …

The recent success of a Plasmodium falciparum malaria vaccine consisting of
circumsporozoite protein (CSP) T and B cell epitopes has rekindled interest in the …

The circumsporozoite protein (CSP) is the main surface antigen of malaria sporozoites, a
prime vaccine target, and is known to have polymorphisms in the C-terminal region …